iOncologi
iOncologi, Inc. is a clinical-stage immuno-oncology company developing next-generation therapies for solid tumors by reprogramming the tumor microenvironment. Our lead candidate, IONC101, is a systemically delivered, mRNA-based immunotherapy in Phase I trials for glioblastoma and pediatric metastatic osteosarcoma. IONC101 encodes for a rational combination of immune-modulating proteins designed to drive effector T cell recruitment, reverse myeloid suppression, and induce local inflammation within the tumor.
Our second program, IONC201, is a chemically defined, synthetic nanoplex platform for receptor-targeted RNA delivery. Unlike lipid nanoparticles, IONC201 offers modularity, tumor-specific targeting, and low immunogenicity. It is IND-ready and initially aimed at EGFR+ tumors.
iOncologi is actively seeking strategic partners for clinical development, co-commercialization, and platform expansion across RNA therapeutics and immuno-oncology.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}